Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2022 Feb;13(1):267-274.
doi: 10.1007/s41999-021-00592-3. Epub 2021 Nov 26.

Sarcopenia assessment by new EWGSOP2 criteria for predicting chemotherapy dose-limiting toxicity in patients with gastrointestinal tract tumors

Emir Celik  1 , Veysel Suzan  2 , Nilay Sengul Samanci  3 , Aysegul Akkan Suzan  4 , Mehmet Karadag  5 , Serdar Sahin  6 , Muhammed Samil Aslan  7 , Hakan Yavuzer  2 , Nebi Serkan Demirci  3 , Alper Doventas  2 , Fuat Hulusi Demirelli  3
Affiliations
Observational Study

Sarcopenia assessment by new EWGSOP2 criteria for predicting chemotherapy dose-limiting toxicity in patients with gastrointestinal tract tumors

Emir Celik et al. Eur Geriatr Med. 2022 Feb.

Abstract

Introduction: In 2019, The EWGSOP2 group made updates on the definition and diagnosis of sarcopenia. The aim of this study is to determine the possible risk factors for chemotherapy dose-limiting toxicity (DLT).

Methods: Newly diagnosed gastrointestinal (GI) cancer patients were included in this prospective observational study. Chemotherapy DLTs were recorded in patients receiving platinum-based therapy. The patients were divided into two groups according to the current sarcopenia criteria.

Results: 75 patients were included in the final analysis. Chemotherapy DLT occurred in 52% (n = 39) of all patients who received platinum-based chemotherapy. DLT rates were 78.9% and 42.9% in sarcopenic and non-sarcopenic patients, respectively (p = 0.007). According to the results of the multivariate analysis, the only sarcopenia was found as a statistically significant risk factor for DLT.

Conclusion: Assessment of sarcopenia evaluated with the current EWGSOP2 diagnostic criteria is useful in predicting chemotherapy DLT development in patients with a diagnosis of GI cancer. In the future, current EWGSOP2 recommendations should be considered while designing a study investigating the correlation between sarcopenia and chemotoxicity.

Keywords: Chemotherapy dose-limiting toxicity; EWGSOP2 criteria; Sarcopenia.

PubMed Disclaimer

References

    1. World Health Organization. Cancer fact sheet. WHO (2017) http://www.who.int/mediacentre/factsheets/fs297/en/ n.d.
    1. Siegel RL, Miller KD, Jemal A (2019) Cancer statistics, 2019. CA Cancer J Clin 69:7–34. https://doi.org/10.3322/caac.21551 - DOI - PubMed
    1. Martin L, Senesse P, Gioulbasanis I, Antoun S, Bozzetti F, Deans C et al (2015) Diagnostic criteria for the classification of cancer-associated weight loss. JCO 33:90–99. https://doi.org/10.1200/JCO.2014.56.1894 - DOI
    1. Miyata H, Sugimura K, Motoori M, Fujiwara Y, Omori T, Yanagimoto Y et al (2017) Clinical assessment of sarcopenia and changes in body composition during neoadjuvant chemotherapy for esophageal cancer. Anticancer Res 37:3053–3059 - PubMed
    1. Choi MH, Oh SN, Lee IK, Oh ST, Won DD (2018) Sarcopenia is negatively associated with long-term outcomes in locally advanced rectal cancer. J Cachexia Sarcopenia Muscle 9:53–59. https://doi.org/10.1002/jcsm.12234 - DOI - PubMed

Publication types

MeSH terms

LinkOut - more resources